Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Nuvig Therapeutics

    Menu

    Nuvig Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nuvig Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089

              Details:

              NVG-2089 is a novel, recombinant, non-immunosuppressive immunomodulator designed to target type II Fc receptors and trigger an endogenous regulatory mechanism. It is being developed for the treatment of inflammatory myopathies and severe dermatologic autoimmune disease.

              Lead Product(s): NVG-2089

              Therapeutic Area: Musculoskeletal Product Name: NVG-2089

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nuvig Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases

              Details:

              Nuvig is building a pipeline of differentiated protein therapeutics that specifically target affected tissues in a disease-specific manner and can be used in the context of varied but well-defined disease mechanisms.

              Lead Product(s): Protein-based Therapeutic

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Novo Holdings

              Deal Size: $47.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing May 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY